Anika Therapeutics Inc. · NASDAQ:ANIK
Anika Therapeutics — Q2 2020 Earnings Presentation
10 slides from Anika Therapeutics's earnings presentation, Jul 30, 2020
Slide 1: Second Quarter 2020 Earnings Call Presentation
SECOND QUARTER 2020 EARNINGS CALL PRESENTATION July 30, 2020 Nasdaq: ANIK
Slide 2: Safe Harbor Statements
SAFE HARBOR STATEMENTS Cautionary Note on Forward-looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company’s commercial capabilities, initiatives and production, its product pipeline and
Slide 3: Our Response to COVID-19 Pandemic
OUR RESPONSE TO COVID-19 PANDEMIC • Taking necessary steps to protect the health and well-being of our employees, patients we serve, and our communities • Strengthening liquidity to navigate the uncertainty of COVID-19 and beyond • Implementing short-term expense controls; Prioritizing key business
Slide 4: Enhanced Global Leadership Team
ENHANCED GLOBAL LEADERSHIP TEAM Bart Bracy Steven Ek Mark Brunsvold James Chase Vice President Vice President R&D President Senior Vice President Sales and Marketing Sports Medicine Sales and Marketing Americas International (Former Co-Founder & (Former CEO, (Former Co-Founder & Executive, Parcus Me
Slide 5: Well-Positioned to Navigate COVID-19
WELL-POSITIONED TO NAVIGATE COVID-19 • Full product continuum of joint pain management, sports medicine and joint preservation, restoration and regeneration solutions • Majority of Anika’s solutions are used in office-based and ambulatory surgery center procedures • Easing COVID restrictions are ena
Slide 6: Accelerated Arthrosurface and Parcus Integration
ACCELERATED ARTHROSURFACE AND PARCUS INTEGRATION • Formed new, enhanced global leadership team • Fully integrated U.S. commercial team to support expanded product portfolio; 35 sales professionals in the U.S. • Completed cross-training commercial team on combined product portfolio • Continued engagi
Slide 7: Growing, Diverse Product Portfolio
GROWING, DIVERSE PRODUCT PORTFOLIO Orthopedic Joint Preservation and Restoration Joint Pain Management • Six new sports medicine surgical • Launch and first sales of CINGAL in devices and instruments used in Australia procedures ranging from rotator cuff • Viscosupplement product regulatory repairs
Slide 8: Q2 2020 Financial Highlights
(1) Q2 2020 FINANCIAL HIGHLIGHTS Dollars in millions Total Revenue $30.4 $30.7 20% $144M Total Revenue Growth Cash & Investments (1H 2020) as of 6/30/2020 Q2 2019 Q2 2020 • Total revenue increased 1% and 20% for 3- and 6-month periods, despite COVID-19 pandemic • Orthopedic Joint Preservation and Re
Slide 9: 2020 Strategic Outlook
2020 STRATEGIC OUTLOOK • New, enhanced global leadership team to successfully navigate the COVID-19 environment and emerge stronger than before • Accelerating integration of acquisitions to form an enhanced organization with renewed purpose and vision • Growing product portfolio across the continuum
Slide 10: Second Quarter 2020 Earnings Call Presentation
SECOND QUARTER 2020 EARNINGS CALL PRESENTATION July 30, 2020 Nasdaq: ANIK